GMP Cytokines Market Forecast to 2029 – COVID-19 Impact, Global Analysis By Application, By Type, and Geography
Cytokines play an important role in regulating innate and adaptive immunity, allowing cells of the immune system to communicate over short distances. Cytokine therapy to activate the immune system of cancer patients has been an essential parameter in cancer therapy and continues to be a significant contributor to clinical cancer research today. Interferonalpha is one of the approved cytokines for the adjuvant treatment of refractory malignancies. Several active investigations have demonstrated the ability of cytokines to limit tumor cell growth through direct or proapoptotic antiproliferative activity.
In addition, some cytokines indirectly inhibit tumor growth by stimulating the cytotoxic activity of immune cells against tumor cells. The effectiveness of cytokine therapy for cancer, coupled with the increase in morbidity, is expected to drive the market in 2027. According to the World Health Organization, in 2019, around 9, 6 million deaths worldwide from cancer.
GMP cytokines are used in cell and gene therapy for the expansion and differentiation of different cell types, ex vivo cultures, and other treatments. In addition, they are used in various tissue engineering products for clinical applications. In addition, extensive research is underway on cytokines to discover new therapeutic approaches for treating chronic diseases. The growth of the GMP cytokines market is mainly due to factors such as the increasing acceptance of cytokines for cancer and autoimmune therapies, and the potential contribution of stem cell therapy. However, the high cost associated with GMP cytokine therapy is believed to hold back the market growth.
In addition, the increasing number of investments and collaborations to develop cytokine-based cancer and autoimmune disease therapies is also expected to drive market growth. For example, in September 2020, Synthekine Inc. raised US$82.0 million through funding rounds. The company is engaged in developing cytokine therapies for the treatment of cancer and autoimmune diseases.
According to Pheonix Research, Due to the COVID-19 pandemic, the Global GMP Cytokines Market Size is estimated to be US$126.63 Million in 2021 and is expected to reach a reacclimate Size of US$226.53 Million in 2028 with a CAGR is 8.32% in 2022-2029.
Based on type, the GMP cytokine market is segmented into TNF, interleukin, growth factor, and others. The growth factor segment accounted for the largest market share in 2019; while the TNF segment is expected to record the highest CAGR in the market during the forecast period. The growth factors segment holds the largest market share due to the high demand for cell culture-based research in wound management, oncology, cardiovascular disease, and other medical fields. For example, the study “Advances in Surgical Application of Growth Factor for Wound Healing” was published in April 2019 and was conducted at Shimane University School of Medicine, Japan.
The GMP cytokines market, by configuration, is segmented into cell/gene therapy, tissue engineering products, and others. The cell and gene therapy segment accounted for the largest market share in 2019; while the tissue engineering products segment is expected to record the highest CAGR in the market during the forecast period.
Major players in the GMP Cytokines market are PeproTech, Akron Biotech, Miltenyi Biotec, ABCAM, Lonza, Sino Biological, Creative Bioarray, Bio-Techne, CellGenix, ReproCELL, Cytiva, and Others.
The “Global GMP Cytokines Market (2022-2029)” is segmented by country, company, type, and application. Industry Players, stakeholders, and other participants in the global GMP Cytokines market will be able to prevail when they use the report as a powerful resource. Segment analysis focuses on sales, revenue, and forecasts by region (country), Type, and Application for 2022-2029.
• Tissue-Engineered Products
• Cell/Gene Therapy
• Growth Factor
Middle East & Africa